Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers Squibb’s schizophrenia treatment Cobenfy (KarXT) has had an unusual odyssey and one that may serve as instructive for future drug discovery. https://t.co/qkft7IUwL0
We’re delighted that PCC member @CVSHealth is making important investments in primary care.
Read more in @HeatherLandi’s recent article for @FierceHealth: https://t.co/QL5wucs81c